RxDoctor Payments Data

Craig Greven, MD

Ophthalmology · Winston Salem, NCNPI 1154304863

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,854 of the $3,521 with a category attached, or 81.1%. 12 manufacturers reported payments, led by Alcon at 27.2% of the total. 2025 is the largest year on record at $1,227, 5.7 times the $214 reported in 2019.

$3,521in general payments, 2019–2025

Across 27 payments — averaging $130.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$958
  • Genentech, Inc.$613
  • Genentech USA, Inc.$606
  • AbbVie$258
  • Apellis Pharmaceuticals, Inc.$214
  • Eyepoint US, Inc.$177
  • plus $696 from 6 others
$354,981in research payments, 2019–2025

Across 38 payments — averaging $9341.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$353K
  • AbbVie$2K

What the payments were for

  • Travel & lodging$66619%
  • Food & beverage$2,85481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,521 in reported general payments places this provider in the 75th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$331,794
Medicare patients
354
Services billed
3,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate36$1,434
Ketorolac Tromethamine21$475
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat15$330
Timolol Maleate23$280
Latanoprost22$194

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →